Sign In
Buy HRTX
$0.447
-0.0032 (-0.711%)
At Close: Jun 03, 2026
Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer
06:55pm, Monday, 28'th Apr 2025
CARY, N.C. , April 28, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the appointment of Mark Hensl
5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms
10:35am, Wednesday, 23'rd Apr 2025
Innovation is at its peak for the Zacks Medical-Drugs industry. AUPH, HRTX, ESPR, PYXS and PSTV may prove to be good additions to one's portfolio.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:55am, Wednesday, 23'rd Apr 2025
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025
04:05pm, Tuesday, 22'nd Apr 2025
CARY, N.C. , April 22, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a c
Best Momentum Stocks to Buy for April 22nd
11:15am, Tuesday, 22'nd Apr 2025
DPMLF, HRTX and FOX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 22, 2025.
New Strong Buy Stocks for April 22nd
08:25am, Tuesday, 22'nd Apr 2025
DPMLF, PAM, MTAL, HRTX and BALY have been added to the Zacks Rank #1 (Strong Buy) List on April 22, 2025.
Heron Therapeutics, Inc. (HRTX) Q4 2024 Earnings Call Transcript
12:07pm, Thursday, 27'th Feb 2025
Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Melissa Jarel - Executive Director, Legal Craig Collard - Chief Executive Off
Heron Therapeutics (HRTX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
10:35am, Thursday, 27'th Feb 2025
Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare wit
Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates
07:45am, Thursday, 27'th Feb 2025
Achieved Q4 2024 GAAP Net Income of $3.6 million Generated full-year 2024 Net Revenue of $144.2 million, up 14% year-over-year Delivered full-year 2024 adjusted EBITDA of $8.6 million Generated ZYNREL
Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025
04:20pm, Thursday, 13'th Feb 2025
CARY, N.C., Feb. 13, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a c
Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina
04:05pm, Monday, 23'rd Dec 2024
SAN DIEGO , Dec. 23, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, announced today the relocation of the Company's
Relief For Heron Therapeutics After The Court Win On Cinvanti
03:01pm, Wednesday, 04'th Dec 2024
Heron Therapeutics won a court case securing Cinvanti's patents until 2035, and removing a significant legal overhang on its largest revenue contributor. The court win allows the company to focus on g
U.S. District Court Upholds Validity of CINVANTI® Patents
04:36pm, Tuesday, 03'rd Dec 2024
— Court Rules in Favor of Heron in Patent Lawsuit Against Fresenius Kabi USA, LLC — SAN DIEGO , Dec. 3, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a c
Heron Therapeutics, Inc. (HRTX) Q3 2024 Earnings Call Transcript
11:45am, Tuesday, 12'th Nov 2024
Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Melissa Jarel - Executive Director Craig Collard - Chief Executive Officer Ir
Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
11:00am, Tuesday, 12'th Nov 2024
Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare wi
